metaPreg - Amlodipine (versus unexposed) during pregnancy

Amlodipine (versus unexposed)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.42 [0.69, 2.93]	0%	3 studies	119	124	not evaluable	ROB	-
Major congenital malformations	1.46 [0.68, 3.15]	0%	3 studies	99	124	not evaluable	ROB	-
Limb defects	3.26 [0.16, 64.54]	-	1 study	3	32	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.52 [0.21, 10.83]	91%	2 studies	105	79	not evaluable	ROB	-
Low birth weight (< 2500g)	0.54 [0.26, 1.15]	-	1 study	61	48	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Gestational diabetes	0.29 [0.08, 1.02]	-	1 study	27	48	not evaluable	ROB	-
Preeclampsia	0.91 [0.45, 1.85]	-	1 study	58	48	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.96 [0.73, 5.23]	-	1 study	64	36	not evaluable	ROB	-
Elective/induced termination of pregnancy	1.44 [0.33, 6.25]	-	1 study	32	38	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	3.67 [0.43, 31.29]	-	1 study	7	36	not evaluable	ROB	-
Hide endpoints reported in only one study ...